Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Treatment Advances in Waldenstrom Macroglobulinemia

Access Activity

Overview / Abstract:

In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.


Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presenceof serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease occurring in older adults, this malignancy accounts for between 1% and 2% of non-Hodgkin lymphomas (Dimopoulos & Kastritis, 2019; ACS, 2018). Whereas patients with low- and intermediate-risk disease have 5-year survival rates of 87% and 68%, respectively, those with high-risk disease have a 5-year survival rate of only 36% (ACS, 2018). Waldenstrom macroglobulinemia is a disease that requires keeping up to date on the knowledge of risk stratification systems, efficacy and safety data for novel therapeutic approaches, and surveillance and management strategies for adverse events associated with novel treatments (i3 Health, 2021). In this activity, Morie Gertz, MD, MACP, will update providers on the latest evidence-based treatment and management plans for patients with WM.


Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.


Discuss predictive and prognostic markers that can individualize treatment selection for patients with WM
Assess emerging efficacy and safety data on novel therapeutic strategies for WM
Evaluate strategies to optimize the safety and tolerability of novel therapies for WM


Feb 14, 2023


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NCPD | 1.0 CPE | MOC | ILNA



Presenters / Authors / Faculty

Morie Gertz, MD, MACP
Chair of Internal General Medicine
Mayo Clinic of Minnesota

Activity Specialities / Related Topics

Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from BeiGene, Bristol Myers Squibb, Merck, and Seagen.

Keywords / Search Terms

i3 Health i3health, hematologyy, Waldenstrom macroglobulinemia, WM, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map